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PROFESSOR THOMAS SCHWARZ, MD
MECHANISMS OF UV INDUCED IMMUNOSUPPRESSION
It is well known that UV radiation in particular the UVB spectrum suppresses the immune
system. However, UV does not cause a general immunosuppression but rather compromises
the immune system in a specific fashion. Topical application of contact allergens onto UV-
exposed skin does not result in sensitization but causes hapten-specific long-term
suppression. This specific immunotolerance is mediated via T cells, which suppress the
immune system in an antigen-specific manner. These T Cells were previously called
suppressor T cells and have been recently renamed regulatory T cells (Tr). UV-induced Tr
which suppress the induction of contact hypersensitivity belong to the CD$þCD25þ sub-
type, they express CTLA-4, bind dectin-2, and release interleukin-10 upon antigen-specific
activation. It was recently shown that UV-induced Tr upon intravenous injection migrate into
the lymph nodes but not into the skin. This explains why intravenously injected Tr prevent the
sensitization but do not suppress the elicitation phase of contact hypersensitivity. However,
when Tr are injected intracutaneously into the ears of sensitized mice the effector phase of
contact hypersensitivity is efficiently suppressed. This migration behavior is due to the
expression of homing receptors. Tr express the lymph node homing receptor L-selectin
(CD62L) but not the ligands for the skin homing receptors E- and P-selectin.
The cytokine inerleukin-12 (IL-12) has been demonstrated to exhibit the capacity to prevent
UV-induced immunosuppression and even to break established UV-mediated tolerance by
yet unknown mechanisms. IL-12 recently was described to exhibit the capacity to reduce UV-
induced DNA damage presumably via the induction of nucleotide excision repair (NER). UV-
induced DNA damage is an essential molecular trigger for UV-mediated immunosuppression,
thus we studied whether the restoring effect of IL-12 is linked to its capacity to reduce DNA
damage. Injection of IL-12 into wild type mice (wt) which were sensitized through UV-exposed
skin deficient in NER were not able to mount an immune response after UV exposure despite
administration of IL-12. This implied that the prevention of UV-induced suppression of CHS
by IL-12 is dependent on properly functioning DNA repair. In contrast, IL-12 exhibited the
capacity to break already established UV-induced tolerance both in wt and Xpa-/-mice,
indicated this effect to be independent of NER. Likewise, adoptive transfer of suppression via
injection of Tr into naı¨ve recipients was inhibited by IL-12 both in wt and Xpa-/-mice. Inhibition
of sensitization by UV is due to the depletion of Langerhans cells (LC) that is triggered by UV-
induced DNA damage. Accordingly, LC depletion by UV was prevented upon injection of IL-
12 into wt but not in Xpa-/-mice. In addition, immunofluorescence staining revealed DNA
damage carrying cells in the regional lymph nodes upon UV exposure. The number of these
cells was remarkably reduced when UP-exposed mice had received IL-12. In turn, IL-12 did
not reduce the number of DNA damage carrying cells in Xpa-/-mice. Taken together, these
data indicate that the prevention of UV-induced inhibition of CHS by IL-12 is linked to its
capacity to induce NER. In contrast, breaking of UV-induced tolerance and the activity of Tr
by IL-12 is independent of Ner and mediated via another yet to be determined mechanism.
These data demonstrate for the first time a link between NER and the prevention of UV-
induced immunosuppression by IL-12.
Professor Thomas Schwarz, MD
University Kiel
Department of Dermatology and Allergology
Kiel, Germany
tschwarz@dermatology.uni-kiel.de
PROFESSOR JOHN A. MCGRATH, MD
INHERITED DISORDERS OF DESMOSOMES
St John’s Institute of Dermatology, The Guy’s, King’s College and St Thomas Hospitals;
Medical School, London, UK
Desmosomes are highly organized intercellular junctions that provide mechanical integrity to
tissues by anchoring intermediate filaments to sites of strong adhesion. These cell-cell
adhesion complexes are found primarily in epithelial tissues but also in the meninges, the
dendritic reticulum cells of lymph node follicles, and the myocardium. They represent the
major intercellular adhesion mechanism in both follicular and interfollicular epidermis,
anchoring keratin intermediate filaments to the cell membrane and bridging adjacent
keratinocytes, and allowing cells to withstand trauma. Initially described as ‘‘discontinuous,
button-like’’ structures of epithelia, desmosomes are now also recognized as signaling
channels composed of an emerging and expanding network of tissue-specific membrane and
membrane-cytoskeletal linker molecules. Over the last eight years, several naturally occurring
human gene mutations in structural components of desmosomes have been reported. These
comprise autosomal dominant or recessive mutations in plakophilin 1, plakophilin 2,
desmoplakin, plakoglobin, desmoglein 1, desmoglein 4, and corneodesmosin. These
discoveries have often highlighted novel or unusual phenotypes, including abnormal skin
fragility and differentiation, and developmental anomalies of various ectodermal appendages,
especially hair. Some desmosomal gene mutations may also result in cardiac disease,
notably cardiomyopathy. This presentation describes the spectrum of clinical features that
may be found in the inherited disorders of desmosomes and highlights the key functions of
several of the desmosomal proteins in tissue adhesion and cell biology.
Professor John A. McGrath, MD
Professor of Molecular Dermatology
St Thomas’ Hospital
St John’s Institute of Dermatology
Lambeth Palace Road
London SE1 7EH
United Kingdom
John.mcgrath@kel.ac.uk
PROFESSOR JAMES G KRUEGER, MD, PhD
PSORIASIS PATHOGENESIS: CELLULAR AND MOLECULAR PATHWAYS OF INFLAM-
MATION
Tremendous progress has been made over the last several years in elucidating underlying
pathways of pathogenic inflammation in psoriasis and in developing targeted therapies
based on a scientific understanding of this disease. There is good evidence that T-cells are
central in disease pathogenesis: skin lesions are heavily infiltrated with memory T-cells and
clonal populations of T-cells have been detected by independent laboratory groups. The
biologic therapies efalizumab (anti-CD11a) and alefacept (a CD2-binding fusion protein)
selectively target T-cells and can induce remission of psoriasis. However, TNF antagonists
have also emerged as highly effective treatments for psoriasis and some have interpreted this
outcome as evidence that innate immune pathways contribute significantly to disease
pathogenesis. To derive an independent, unbiased view of disease pathogenesis, my group
has performed a series of studies in which large-scale gene expression in psoriasis has been
measured in 1) normal or non-lesional skin, 2) psoriasis plaques, and 3) psoriasis plaques
during treatment with a variety of immune-targeted therapies. These studies provide the first
complete definition of a human ‘‘autoimmune’’ disease in molecular terms. More than 1300
genes have altered expression in psoriasis and many of these genes are related to infiltrating
leukocyte subsets and to molecular pathways of inflammation. One pathway that emerges is
a ‘‘Type 1’’ inflammatory cascade which begins with up-regulated IL-23, which then
activatesTh1/Tc1 T-cells, leading to interferon-g and TNF release, and subsequent activation
of STAT1, with downstream activation of 450 inflammatory genes regulated via STAT1.
Expression of genes on this pathway are strongly related to T-cell infiltrates in skin lesions,
since targeted therapies like cyclosporine, alefacept, and efalizumab suppress them to
baseline levels. Recruitment of T-cells and neutrophils into psoriasis lesions and these cells
may be critical links between innate immunity and acquired immunity in the skin. We have
identified a new type of dendritic cell (DC) marked by expression of the integrin CD11c that
also synthesizes the enzyme iNOS (inducible nitric oxide synthase). The CD11cþ , iNOS-
producing DC is present in very large numbers in the psoriasis lesion such that it is more
abundant that T-cells in some cases. The CD11cþDC is found only in the dermis in normal
skin, but epidermal and dermal CD11cþDCs are found in active psoriasis lesions. The
expression of iNOS by this DC is important, since the product of this enzyme is nitric oxide, a
molecular that has inflammatory and cell-damaging properties. The presence of active
psoriasis is tightly associated with CD11cþDCs and therapy-induced disease resolution is
also tightly associated with elimination of this cellular subset. There must be a critical
interaction between CD11cþDCs and T-cells, since T-cell targeted biologic therapies induce
major reductions in this DC type. However, CD11cþDCs also expresses TNF at high levels,
so these cells might be the main target of TN F inhibitors in psoriasis. Finally, genomic studies
indicate unexpected expression of several lymphoid organizing chemokines in psoriasis
lesions. These chemokines, which include CXCL19, CXCL21, SDF-1, and Bonzo-receptor
ligand, may be the driving force for maintaining organized T-cell and DC infiltrates in psoriasis
plaques. Overall, the cellular and molecular environment of psoriasis lesions is similar to T-
cell-rich regions of lymph nodes, so psoriasis may actually represent formation of a lymphoid
organ in the skin and this would account for the chronic persistence of psoriasis lesions (if
disease is untreated). While further clinical trials with targeted therapeutics will be needed to
fully test these models, much has already been learned about cellular and molecular
pathways of pathogenesis and we should be able to continue to develop of better and safer
treatments for psoriasis based on solid scientific principles.
Professor James G. Krueger
The Rockefeller University
Department of Investigative Dermatology
New York
USA
kreugej@rockefeller.edu
PROFESSOR ARUN DHARMARAJAN
SECRETED FRIZZLED RELATED PROTEIN-4 (SFRP-4) AND ITS ASSOCIATED WNT
SIGNALING PATAHWAYS IN DIFFERENTIATION INDUCED APOPTOSIS IN HUMAN
EPIDERMAL KERATINOCYTES
A. Dharmarajan1, A. Unni1, F. Wood2, D. Keeney3
1School of Anatomy and Human Biology, The University of Western Australia, Perth 2Burn
Centre, Royal Perth Hospital, Perth 3Division of Dermatology, Vanderbilt University,
Nashville, TN, USA
Background: Squamous differentiation in the epidermis involves cell cornification and
(orthokeratotic) death. Epidermal cell death has been studied mainly in undifferentiated
proliferating cell cultures. Typically in these models, damaging agents (physical, chemical) are
used to induce widespread, synchronous cell death. Cell death associated with squamous
differentiation is poorly understood. Our studies address this void in our knowledge of
mechanisms regulating ‘‘differentiation–induced programmed cell death,’’ processes critical
to a competent epidermal barrier.
We hypothesize that a novel secreted Frizzled-related protein (sFRP), sFRP-4, functions to
facilitate squamous differentiation and programmed cell death in the epidermis.
Methods: Immunocytochemistry was used to determine the protein levels of sFRP-4 in
human skin. Quantitative PCR (qPCRF) was used to quantitated sFRP-4 expression and
differentiation-specific gene markers in normal human epidermal keratinocytes (NHEK).
Apoptosis was assessed by DNA fragmentation assay.
Results: We detected transcripts encoding sFRP-4 in NHEK cell cultures. Several Wnts
(Wnt2, 3a, 4, 5a, 6, 7a, 8b, 10b, 16(1) and 16(II)), b-catenin, and Frizzled 4 were also detected
by PCR in NHEKs. SFRP-4 immunoreactivity was pronounced in basal (proliferating)
keratinocytes, in both cytoplasm and nuclei. Inverse pattern was observed when cytoplasmic
b-catenin (triton-soluble fraction) levels were analysed in NHEKs by Western blotting. Low
molecular weight DNA (¼ 100–500 bp) increased quantitatively during the second week of
differentiation, when the granular cell phenotype develops.
Conclusion: these results support that sFRP-4 may function in differentiating keratinocytes
to counter the proliferative effects of canonical Wnt signaling and to regulate the process of
programmed cell death that occurs during squamous differentiation.
Professor Arun Dharmarajan
The University of Western Australia
School of Anatomy and Human Biology
Nedlands WA 6009
Australia
dharma@anhb.uwa.edu.au
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PROFESSOR FIONA M. WOOD, AM CitWA
SKIN REPAIR IN BURN WOUND HEALING–THE POTENTIAL OF TISSUE ENGINEERING
Expedient wound repair is the key to optimizing the outcome from burn injury functionally and
cosmetically.
The use of tissue culture techniques have been explored over the last two decades. The
development of skin substitute has been facilitated by the collaboration between biological
science and engineering. The mechanisms of influence on the wound surface is wide
ranging–maintenance of a moist wound healing environment, vehicle for cytokine delivery,
introduction of architectural framework for cell ingrowth, introduction of an autologous cell
population.
As we review the experience of the last two decades with all areas, science, engineering,
and clinical, we begin to understand the potential of tissue engineering.
Currently, tissue guided regeneration using autologous cell seeding of templates
demonstrated the potential of tissue self assembly. The development of tissue engineering
of skin repair and the future will be discussed.
Professor Fiona M. Wood
Director
McComb Foundation
Perth WA
Australia
fionaw@mccomb.org.au
DR SHELLEY GORMAN
CD4þ T REGULATORY CELLS ACCUMULATE IN LYMPH NODES OF MICE IRRADIATED
WITH UVB
S. Gorman, J. W-Y. Tan, P. H. Hart
Telethon Institute for Child Health Research, University of WA, Perth
Background: Ultra-violet B (UVB) radiation (280–320 nm) is an important environmental
factor known to induce skin neoplasms as well as suppressing tumor-specfic immune
responses. The mechanisms required for the induction of systemic immunomodulation by
UVB radiation have not been identified.
Method: The effect of UVB irradiation (8 kJ/m2; three minimal erythmal doses) upon naı¨ve
lymph node CD4þT cells from BALB/c or congenic DO11.10 mice (TCR specific for the
OVA323–339 peptide) was investigated. An in vitro CFSE proliferation assay was used to
measure activation (CD69, CD25), proliferation, and cytokine production (IFNg, IL-10, IL-2,
TGF-b) by CD4þT cells isolated from skin draining lymph nodes (SDLN) of UVB-irradiated
and control DO11.10 mice. Real-time PCR analysis was used to determine the expression of
the transcription factor FoxP3 in various CD4þT cell populations. Contact hypersensitivity
responses (CHS) to hapten were tested in BALB/c mice after the adoptive transfer of CD4þT
cells purified from SDLN of irradiated and control mice.
Results: There were increased numbers of regulatory CD4þCD25þT cells in SDLN of UVB-
irradiated mice. The CD4þCD25þ cells expressed high levels of FoxP3 and CTLA-4, both
markers of regulatory cells. CD4þT cells from UVB-irradiated mice had a diminished
capacity to respond to presentation of OVA when cultured with dendritic cells (DC). Removing
CD4þCD25þ cells from the CD4þpopulation from irradiated mice completely abrogated
this suppressive effect. Adoptive transfer of CD4þT cells from irradiated mice significantly
suppressed CHS responses.
Conclusion: UVB irradiation of naı¨ve mice induces a population of CD4þT regulatory cells in
the SDLN. These cells modulate immune responses to experimental haptens, and other
antigens and may contribute to the immunomodulatory effects of UVB.
Dr Shelley Gorman
Telethon Institute for Child Health Research
100 Roberts Rd
Subiaco WA 6008
Australia
shelleyg@ichr.uwa.edu.au
DR ANIL KURIEN
EFFECTS OF 370NM UVA AND 300NM UVB COMPARED TO SSUV RADIATION IN
HEALTHY HUMAN VOLUNTEERS
Dr Anil Kurien, Prof Gary Halliday, Prof Ross Barnetson, Dr Diona Damian
Dept of Dermatology, Melanoma and Skin Cancer Research Institute, University of Sydney at
Royal Prince Alfred Hospital, Sydney
Background: Ultraviolet radiation induced immunosuppression can augment cutaneous
carcinogenesis. Although UVB is known to be immunosuppressive, UVA has been reported to
have immunosuppressive or immunoprotective effects. We aimed to compare and contrast
the effects of discrete UVB and UVA wavebands on contact hypersensitivity (CHS) responses
to nickel in nickel-allergic volunteers. These effects were also compared to those of solar-
simulated UV (ssUVR) radiation (UVBþUVA).
Method: Healthy nickel allergic volunteers were irradiated with six different doses of ssUVR
on one side of the back and five different doses of a single waveband of UVA or UVB on the
other side. Discrete wavebands of 370nm or 300nm were obtained with the use of
interference filters. Volunteers were then patch tested with nickel, 48 hours post irradiation.
The intensity of CHS responses in irradiated and unirradiated areas on the back was
noninvasively measured 72 hours after patch testing, with a reflectance erythemameter. By
comparison of nickel reactions in irradiated sites with those at unirradiated control sites, the
degree of immunosuppression with each dose and waveband of UV was determined.
Results: We found that in the first group of volunteers 300nm UVB caused dose dependent
increase in immunosuppression with ssUV showing a similar pattern. In the second group,
370nm UVA was immunosuppressive at moderate doses equivalent to about 6 min of summer
sunlight but had immune-enhancing effect at higher doses equivalent to about 22 min of
sunlight. Irradiation with 370nm UVA also appeared to attenuate the level of ssUV induced
immunosuppresion observed on the contra lateral back. Volunteers in the first group were
crossed over to receive 370nm and vice versa after about 3 months and we found that whilst
there was a high level of ssUV induced immunosuppresion in the 300nm group, in the 370nm
group it was diminished.
Conclusion: Three hundred and seventy nm UVA was immunosuppressive at moderate
doses but immunoprotective at high doses, and attenuated the ssUV induced immunosup-
pression on the contralateral side.
Dr Anil Kurien
Royal Prince Alfred Hospital
Department of Dermatology
Camperdown, Sydney
NSW, Australia
anilmk@med.usyd.edu.au
MISS JACQUELINE MCGLADE
THE EFFECT OF ULTRAVIOLET-B RADIATION ON MURINE ASTHMA MODELS
J.P. McGlade, J.C. Lenzo, D.J. Turner, W.R. Thomas, P.H. Hart
Telethon Institute for Child Health Research, University of WA, Perth
Background: Ultraviolet-B (UVB) radiation (280–320 nm) can alter both Type 1 and Type 2
immune responses. This study investigated the effects of UVB on two different models of
allergic asthma using papain and ovalbumin (OVA). As UVB was applied to the skin whilst the
allergens were applied to the peritoneal cavity and/or respiratory system, this represents a
truly systemic model of immunomodulation by UVB.
Method: In the papain model, C57BL/6J mice were exposed a single dose of UVB on shaved
dorsal skin three days prior to intranasal sensitization, boost or challenge with the cysteine
protease. In the OVA model, BALB/c mice were exposed to a single dose of UVB at the same
time points. For sensitization and boost, OVA was administered intraperitoneally with alum
whilst the challenge consisted of a single OVA saline aerosol. In both models, levels of
allergen-specific immunoglobulin(Ig)E, IgG1 and IgG2a were measured in serum and levels of
interleukin(IL)-4, IL-5, IL-10, interferon(IFN)-g and prostaglandin(PG)E2 were measured in
bronchoalveolar lavage (BAL) fluid. Differential cell counts were performed on the BAL fluid
and histological analysis performed on the lung tissue. In addition, the effect of UVB exposure
on airway hyperresponsiveness in the OVA model was also determined.
Results: In the papain model, UVB before sensitization reduced papain-specific IgE titres
whilst increasing levels of IL-4, IL-10 and PGE2. In the OVA model, levels of IL-4, IL-5, IL-10,
IFN-g, and PGE2 were significantly decreased in mice that received UVB before sensitization
or before boost. Additionally, UVB before sensitization significantly suppressed the induction
of airway hyperresponsiveness. For both models, no significant changes were noted in any of
the other parameters measured.
Conclusion: UVB regulated immune responses in two different models of allergic asthma.
These findings also indicate that different compartments of the immune system (serum,
lavage fluid, lung tissue) may be regulated independently by UVB.
Miss Jacqueline McGlade
Telethon Institute for Child Health Research
Department of Molecular Biotechnology
100 Roberts Road
Subiaco WA 6005
Australia
jacquelinem@ichr.uwa.edu.au
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PROFESSOR GARY M. HALLIDAY
B CELLS ACTIVATED IN LYMPH NODES IN RESPONSE TO ULTRAVIOLET-IRRADIATION
OR BY INTERLEUKIN-10 INHIBIT DENDRITIC CELL INDUCTION OF IMMUNITY
Gary M. Halliday and Scott N. Byrne
Department of Medicine, Dermatology Research Laboratories, Melanoma and Skin Cancer
Research Institute, Sydney Cancer Centre, Royal Prince Alfred Hospital at the University of
Sydney, 2006, Australia
Background: Ultraviolet radiation suppresses systemic immunity, a critical event in skin
carcinogenesis. The mechanism of this suppression is not totally understood and is central to
our ability to develop therapeutic lines of attack.
Method: We explored these cellular mechanisms by exposing mice to systemically
immunosuppressive doses of ultraviolet radiation and then analyzing lymph node cell
phenotype by flow cytometry, and immune function in the lymphoid organs by adoptive
transfer.
Results: While ultraviolet radiation increased total cell number in the draining lymph nodes, it
did not alter the activation state of dendritic cells. Rather, ultraviolet radiation selectively
activated lymph node B cells, with these cells being larger and expressing higher levels of
both MHC II and B220 but not co-stimulatory molecules. This phenotype resembled that of a
B cell geared towards immune tolerance rather than activation. To test whether ultraviolet
radiation-activated B cells were responsible for immunosuppression, dendritic cells and B
cells were conjugated to antigen ex vivo and transferred into naı¨ve hosts. While dendritic cells
by themselves activated T cells, when the B cells from ultraviolet radiation-irradiated mice
were co-injected with dendritic cells, they suppressed dendritic cell activation of immunity.
Interleukin-10-activated B cells also suppressed dendritic cell induction of immunity,
suggesting that Interleukin-10 may be involved in this suppressive effect of ultraviolet
radiation.
Conclusion: These results demonstrate a new mechanism of ultraviolet radiation-immuno-
suppression whereby ultraviolet radiation activates B cells in the skin-draining lymph nodes,
which can suppress dendritic cell activation of T cell-mediated immunity.
Professor Gary Halliday
Dermatology Research Laboratories
Blackburn Building D06, University of Sydney
Sydney, NSW, 2006,
Australia
garyh@med.usyd.edu.au
DR STEPHEN GILMORE
SKIN CANCER CELL DYNAMICS AND THE ERROR CATASTROPHE: THE THEORETICAL
BASIS OF A NOVEL THERAPEUTIC STRATEGY
Dr Stephen Gilmore
The quasispecies model, first theorized by Eigen in 1971, describes the dynamics of
populations of self-replicating strings subject to selection and mutation. Computer
simulations suggest such populations may self-organize to a state where they maintain their
genetic information yet maximize their search speed of genetic space – the error threshold.
Populations of pathogenic viruses have recently been shown to exist at the error threshold
hence, they are able to maintain both genetic integrity and diversity – the latter enabling them
to keep one step ahead of immune responses. Although normal eukaryotic cells live well
inside the phase transition characterized by the error threshold it has been suggested that
tumor cells – which are known to exhibit high mutation rates – may exist, like pathogenic
viruses, in the critical regimen, where they can propagate their genetic information accurately
yet maintain enough genetic diversity to escape immune-mediated elimination. However, life
at the error threshold comes at a price – increase the mutation rate slightly above threshold
and the error catastrophe sets in. Genetic information can no longer propagate and the
population drifts through genetic space leading to non-viability and death.
Here I present the results of new and preliminary computer simulations that illustrate the
quasispecies concept. From the perspective of artificial life modelling, I am able to
demonstrate that binary strings can evolve to the error threshold on a fractal fitness
landscape, where the mapping from genotype to phenotype is modelled by computation
within a simple one-dimensional cellular automata. The results are then discussed in the
context of in-situ cutaneous neoplasms, where the implications for therapeutic intervention
are clear: increase the mutation rate slightly and the tumor population vanishes, leaving the
normal cells unharmed.
Dr Stephen Gilmore
University of Melbourne,
Department of Medicine (Dermatology),
St. Vincent’s Hospital,
Fitzroy, Victoria,
AUSTRALIA.
fjheale@netspace.net.au
DR SALLY DE ZWAAN
FAMILY CLUSTERING OF EARLY-ONSET BASAL CELL CARCINOMA OF THE SKIN
S. de Zwaan1, G.J. Mann1
1Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium
Institute, Westmead NSW 2145
Background: Basal cell carcinoma (BCC) is the most prevalent cancer in Australia, and sun
exposure is known to be the major external cause. Little is known about individual genetic
susceptibility to this disease except that fair-red skin types are at increased risk in part due to
the presence of variants in the melanocortin-1 receptor. Mutations in the patched gene
(9q22.3) are responsible for the rare familial BCC predisposition syndrome nevoid basal cell
carcinoma syndrome (NBCCS), and this gene is a candidate for causing high susceptibility to
BCC outside this specific syndrome.
Method: Fifty-six adult probands from the Sydney metropolitan area who had histologically
proven early-onset BCC (o40 yr) were recruited, as well as 203 of their first-degree relatives.
All subjects were interviewed to determine their family structure and cancer histories. All
reports of cancer were confirmed through state cancer registries or the treating doctor (for
non-melanoma skin cancers). The oldest unaffected sibling (if available) was designated as a
control. Peripheral blood for genotyping was collected from probands, their sibling pairs, and
their parents. Probands were screened for variants in all 23 exons of the patched gene using
PCR, dHPLC screening, and direct sequencing of those with abnormal dHPLC results.
Probands and sibling controls were examined for pigmentary characteristics by reflectance
spectrometry and for signs of solar skin damage.
Results: Data have so far been analyzed for family history of cancer and the prevalence of
patched variants. Two thirds of reported cancers were confirmed, with 41% of probands
having a confirmed history of BCC in first-degree relatives, while in 16% two or more were
affected. Thirty-three percent had a confirmed history of SCC in a first-degree relative and
5% a melanoma. No mutations were seen in any exon of patched in probands, and
polymorphisms were seen largely in the proportions expected in the general population.
Conclusion: Cases of early-onset BCC commonly occur in strong familial clusters, but the
specific causes remain to be elucidated. However, patched mutations are unlikely to be
responsible outside the context of NBCCS.
Dr Sally de Zwaan
Genetic Epidemiology Group, WICR
Westmead Millennium Institute
Darcy Rd
Westmead NSW 2145
Australia
sally_dezwaan@wmi.usyd.edu.au
DR RHONDA KWONG
EFFECTS OF E2F-1 OVER-EXPRESSION IN HEAD AND NECK SQUAMOUS CELL
CARCINOMA CELL LINES AFTER TREATMENT WITH EPIDERMAL GROWTH FACTOR
RECEPTOR TYROSINE KINASE INHIBITION BY IRESSAt (GEFITINIB) AND E2F-2 DECOY
MOLECULES
Rhonda A. Kwong1,2, Toby H. Corlette2, Larry H. Kalish2, Gary Halliday1, Ross Barnetson1,
Elizabeth A. Musgrove2, Robert L. Sutherland2
1Dermatology Research Laboratory, Central Clinical School, University of Sydney 2Cancer
Research Program, Garvan Institute of Medical Research, Darlinghurst 2010
Objective: Head and neck squamous cell carcinoma (HNSCC) is the ninth most common
diagnosed cancer in Australia and disease incidence continues to increase in females.
Despite improvements in surgery, chemotherapy, and radiotherapy, morbidity and mortality
rates remain high. Understanding the biology of HNSCC has identified common aberrations,
such as E2F-1 and epidermal growth factor receptor (EGFR) over-expression, which may be
utilized as molecular chemotherapeutic targets, predict treatment response and disease
outcome, or generate improved follow-up strategies. Iressat (gefitinib) is an EGFR tyrosine
kinase inhibitor. Over-expression of E2F-1 is associated with aggressive HNSCC and may
represent a mechanism of resistance to gifitinib. Moreover, E2F-1 activity may be inhibited by
decoy molecules in vitro and in vivo, which may alter response to gefitinib.
Methods: HNSCC cell lines over-expressing E2F-1 treated with variable doses of gefitinib
and/or E2F-1 decoy molecules were harvested at time points with matched controls. Cell
proliferation rates and doubling times were determined by hemocytometer cell counts. Cell
cycle phase distribution following propidium iodide staining and active S phase measurement
through BrdU incorporation were examined through FACS analysis.
Results: Over-expression of E2F-1 conferred resistance to gefitinib to SCC9 cell lines, which
continued to proliferate and form colonies at all gefitinib concentrations and doses of
radiotherapy. The control cells demonstrated a G1 block 24 hours after ZD1839 dosing. At 96
hours after dosing, active S phase measurements were 3% for controls while the E2F-1 over-
expressing cells were largely unaltered. Work is currently being undertaken with the E2F-1
decoy molecules.
Conclusion: Over-expression of E2F-1 confers chemoresistance to HNSCC through
inhibiting not only cell cycle arrest but also anti-proliferative effects of gefitinib treatment
in vitro. Over-expression of E2F-1 may predict for patients where gefitinib treatment is not
likely to be effective.
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DR WENDY LIU
THE BRAF (T1799A) MUTATION IS ASSOCIATED WITH DISTINCT CLINICAL CHARAC-
TERISTICS IN INVASIVE PRIMARY MELANOMA
W. Liu1,2, W. Murray1, J. Dowling2, J. Kelly2, R. Wolfe3, G. Mason4, J. Magee5, C. Angel6, A.
Dobrovic1, G. McArthur1
1Peter MacCallum Cancer Centre, 2The Alfred Hospital, 3Monash University, 4Melbourne
Pathology, 5Dorevitch Pathology and 6Gribbles Pathology. Melbourne, Victoria, Australia
Background: Mutation in the BRAF gene, predominantly a single base substitution
(T1799A), has been found in 66% of malignant melanomas. BRAF (T1799A) encodes an
activated form of BRAF (V600E) that leads to activation of the RAS/RAF/MAPK pathway.
Despite a large number of studies, the clinical and pathological associations of T1799A in
primary melanoma remain poorly understood. The objective of this study was to assess the
clinical features of primary melanomas containing the T1799A mutation.
Method: Two hundred and sixty-four patients with 265 invasive primary melanomas were
prospectively interviewed and examined with respect to their melanoma characteristics and
risk factors. Independent pathological reviews were performed. All primary melanomas were
screened with allele-specific PCR for the T1799A mutation. The allele-specific PCR technique
allows for detection of 2% mutant DNA when mixed with wild type DNA.
Results: Of 265 tumor samples, 251 (95%) samples were successfully amplified. The
T1799A mutation was found in 112 (45%) of the primary melanomas. Univariate analysis
revealed the following parameters as significant associations of the T1799A mutation
(Po0.05): low tumor thickness; low mitotic index; superficial spreading melanoma (SSM);
pigmented melanoma; intermittently sun-exposed sites; the lack of a history of solar
keratoses; younger age; fewer freckles. When all competing associations were entered into a
multivariate logistic regression model, four clinical variables remained as independent
associates of T1799A mutation: 1) Individuals with fewer freckles (OR 5.4, 95% CI 1.9-15.1,
P¼ 0.001); 2) SSM (OR 7.3, 95% CI 1.3-40.3, P¼ 0.024; lentigo maligna melanoma, reference);
3) Pigmented melanoma (OR 4.3, 95% CI 1.0-18.3, P¼ 0.047; amelanotic melanoma,
reference); 4) Individuals with no history of solar keratoses (OR 3.0, 95% CI 1.0-9.0, P¼ 0.053).
Conclusion: In primary invasive melanoma, the T1799A mutation has distinct associations
with host phenotype, environmental sun exposure pattern, tumor histological type and cellular
activities in pigment production.
Dr Wendy Liu
Research, Level 2
Peter MacCallum Cancer Centre, St. Andrew’s Place
East Melbourne, VIC 3002, Australia
wendy.liu@petermac.org
DR ANGELO SKLAVOS
GENOTYPE-PHENOTYPE STUDIES IN CDKN2A(p16INK4a/p14ARF) MUTATION POSI-
TITVE AND NEGATIVE AUSTRALIAN HIGH-RISK MELANOMA FAMILIES
A.V. Sklavos1, E. Holland1, R.F. Kefford1, E. Gow2, G.J. Mann1
1Westmead Millennium Institute at the University of Sydney; 2Skin and Cancer Foundation
Australia; Westmead Hospital Department of Dermatology
Background: CDKN2A is a highly penetrant gene for melanoma (CMM) susceptibility. We
have reported that mutation carriers within multiple-case CMM families exhibit higher median
nevus counts than non-carriers, the most potent clinical risk factor for CMM. Most families
with  3 cases of CMM do not have identifiable germline mutations. Phenotyping of such
families (not linked to chromosome 9p and CDKN2A mutation negative) have been performed
to further define the genetic correlates of nevus formation and CMM.
Methods: Carrier, non-carrier, and unrelated members of multiple (  3) case CMM families
have been evaluated in a blinded fashion by counting banal and clinically atypical nevi. The
families include 9 (n¼ 78) with high-risk alleles of the CDKN2A gene (-34G4T, Ala36Pro,
Ile49Ser, Met53Ile, Gly67Ser, Asn71Ser) and 12 families without CDKN2A or CDK4 mutations
(n¼ 75). Some of these families link to a novel locus at chromosome 1p22; CMM affection
status was used as a surrogate marker of positive mutation status.
Results: As expected, subjects affected with CMM from CDKN2A mutation negative families
are similarly noted to have increased total nevus counts 42mm (po0.001), counts of larger
(45mm, po0.001) and clinically atypical nevi (po0.001) compared with unaffected relatives
and spouse controls. There are no statistically significant differences in counts between CMM
cases in mutation negative families and CDKN2A mutation positive cases or in comparisons
with CDKN2A mutation carriers generally.
Conclusion: CMM cases show high nevus counts, irrespective of their CDKN2A mutations
status. Furthermore, the previously described difference in nevus counts between CDKN2A
carriers and non-carriers when much less marked when CMM cases were excluded (although
numbers in that analysis are small due to the high segregation of CMM). We conclude that
nevogenic risk factors are common in familial CMM irrespective of mutation status and that
CDKN2A mutations largely act in concert with them to raise nevus counts.
Dr Angelo Sklavos
Melanoma Group, Westmead Institute for Cancer Research
Westmead Millennium Institute
Darcy Road WESTMEAD NSW 2145
asklavos@student.usyd.edu.au
DR DOMINIC MALLON
THE GENE EXPRESSION PROGRAM OF LESIONAL SKIN IN ATOPIC DERMATITIS
Kate Holt1, D. Mallon2, Ben Cocks3, Pat Holt1
1Cell Biology, TVW Institute for Child health Research 2Department of Immunology,
Fremantle Hospital, 3Incyte Genomics
Background: Previous studies of pathogenesis of atopic dermatitis (AD) have utilized skin
from normal subjects or skin from psoriasis as comparators. In this study we sought to use
gene microarray to determine the gene expression program in lesional versus non-lesional
skin within each of 8 subjects with moderate to severe AD.
Methods: Eight adult subjects with moderate to severe AD (SCORAD450) were recruited as
part of the Perth Atopic Dermatitis Study. Each had biopsies obtained from lesional and non-
lesional skin and microarray analysis was used to determine differentially expressed genes.
Results: Four hundred fifty-six transcripts were identified whose abundance differed
significantly in at least 7/8 subjects (T-test, po0.05) Of these, 390 could be mapped to
human mRNA sequences in GenBank. The transcripts were clustered hierarchically into 5
clusters; Cluster 1–highly upregulated in all patients (n¼ 27); Cluster 2–highly upregulated in
3; upregulated in an additional 4 (n¼ 33); Cluster 3–moderately upregulated in most subjects
(n¼ 161); Cluster 4–downregulated in most patients (n¼ 99); Cluster 5–downregulated in at
least 7/8 subjects (n¼ 145). Differentially expressed genes included those involved with
keratinocyte activation, the cytoskeleton, cornified envelope, extracellular matris, extra-
cellular proteases, defensins, and cytokines, with a number encoded in chromosomal loci
previously linked to AD.
Conclusion: Gene microarray is a powerful tool to determine the gene expression program
of lesional versus non-lesional skin within individuals with AD.
Dr Dominic Mallon
Fremantle Hospital
Immunology Department
Alma Street
Fremantle WA 6160
D.Mallon@health.wa.gov.au
DR JOSEPH ROTHNAGEL
IDENTIFICATION OF THE HUMAN HOMOLOG TO FLG2: A FILAGGRIN-LIKE GENE THAT
IS EXPRESSED LATE IN EPIDERMAL DIFFERENTIATION
Pawel Listwan and Joseph A. Rothnagel
The University of Queensland, St Lucia, 4072, QLD, Australia
One of the most prominent markers of late epidermal differentiation is filaggrin, which is
synthesized as a large short-lived phosphorylated polyprotein (profilaggrin). Profilaggrin
initially forms the keratohyalin granules characteristic of the granular layer but is subsequently
processed to release individual filaggrin subunits. These subunits interact with keratin
filaments to form highly ordered structures known as macrofibrils and are later degraded to
free amino acids, which are postulated to produce the high osmolarity necessary for the
retention of water by the stratum corneum. We have identified a gene located on
chromosome 1q21 that has the same structural organization as profilaggrin, trichohyalin,
and repetitin. A search of the genomic and protein databases revealed that this gene encodes
a hitherto uncharacterized protein. The conceptually translated protein contains two calcium-
binding domains of the EF-hand type at its N-terminal, followed by a unique sequence and
then several repetitive units that vary in size between 76–77 residues. Each repeating unit has
a pI of 8.5 and is rich in glycine, serine, glutamine, and histidine and has limited sequence
homology with filaggrin. Northern blot analysis revealed a single transcript (48 kb) that is
expressed in high levels in the epidermis and is not found in any other epithelia. A polyclonal
antibody produced using a synthetic peptide derived from the conceptually translated ORF,
detects both high and low molecular weight products in western blots of epidermal extracts
consistent with processing of a polypeptide precursor. Double-label immunofluorescence
localized the novel protein to the granular and cornified layers of the epidermis. The
identification of this novel protein that is structurally and functionally related to (pro)filaggrin
as well as the recently identified filaggrin-like protein, hornerin, suggests a high degree of
redundancy in this class of protein. The similarities with profilaggrin also make it a candidate
for ichthyosis vulgaris and perhaps other genodermatoses as well.
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ELEVATED MUTANT KERATIN 5 mRNA EXPRESSION IN A NOVEL DELETION MUTATION
IN DOWLING-MEARA EPIDERMOLYSIS BULLOSA SIMPLEX
M.W. Kempy, S. Klingbergw, L. Lloydw, T.J. Molloyy, P. MarrF, Y. Wangy, G.A.C. Murrelly,
D.F. Murrell
Department of Dermatology, yOrthopaedic Research Institute, FDepartment of Anatomical
Pathology, The St George Hospital Campus, University of New South Wales, Sydney, NSW,
wDepartment of Chemical Pathology, Queensland Health Pathology Service, Royal Brisbane
Hospital Campus, QLD, Australia
Background: Epidermolysis bullosa simplex (EBS) is a group of blistering skin diseases that
share the common feature of deriving from mutations in the genes encoding the intermediate
filament proteins keratin 5 and keratin 14, found within basal keratinocytes. Here we report an
investigation into the relative levels of mutant and wild type keratin 5 mRNA transcripts in an
attempt to delineate the relationship between genotype and phenotype in a female patient
expressing a strikingly mild form of EBS–Dowling Meara that had ameliorated with age.
Method: The subjects of this study were a 3-generation non-consanguineous Australian family
of Caucasian extraction. The proband was the only member of the family to exhibit clinical
symptoms of EBS. Genomic DNA was isolated and selectively amplified to allow keratin 5 and
keratin 14 sequence analysis using standard techniques. Using the 15 nucleotide difference
between the wild type and mutant alleles, differential primers were designed to selectively
amplify either wild type or mutant alleles. qPCR was performed using the Corbett Rotorgene
3000 (Corbett Research) and the dsDNA binding fluorescent dye, SYBRt Green I (Invitrogen).
All calculations were performed against the results from amplification of the human reference
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Results: The analysis of the K5 and K14 genes from the proband resulted in the finding of a novel
deletion mutation in the 2B helical region of keratin 5, resulting in the deletion of 5 amino acid
residues–arginine, asparagine, lysine, leucine, alanine in positions 429–433 inclusive (del RNKLA
429–433). Data analyzed using comparative quantitation against a reference gene (GAPDH) as
has previously been outlined in the literature (Livak and Schmittgen, 2001). Five replicates showed
DDCT values for the mutant allele were 2.7 fold greater than the wild type DDCT values.
This is the first report of a nonmissense mutation in the gene encoding keratin 5, which
leads to the development of EBS-WC. Interestingly, the deletion of a relatively large
sequence of amino acid residues in a highly conserved region, has in this instance, led to
the development of a surprisingly mild phenotype. It is possible that, as this mutation does
not affect the amino acid reading frame, the net disruption to the mature protein is
minimized. Secondly, the alpha helical conformation of the 2B domain of keratin 5 appears
to be reasonably resistant to aberrations in helical structure. We hypothesized that the mild
phenotype of EBS-DM resulting from this mutation may have been due to a reduced level of
the mutant mRNA, either from decreased expression or enhanced transcript turnover due
to a surveillance process such as mRNA interference. Interestingly, qPCR analysis of the
mutant and wild type alleles found that the mutant allele was present in biopsy samples at a
level 2.7 fold higher than the wild type allele. This finding was surprising given the especially
mild form of EBS-DM displayed by the proband.
Conclusion: This finding may support the view that the 2B domain of keratin 5 is quite resilient
to disruption of the helical structure. It also lends weight to the argument that the phenotypic
expression of EBS is dependent upon the complex interplay of the form and location of a
pathogenic mutation in keratins 5 and 14. In conclusion, this report gives further insight into the
complicated disease mechanisms that relate genotype to phenotype, and assists in
understanding why a simple missense mutation in one region of a keratin gene may lead to
a far more severe disease phenotype than a multi-nucleotide deletion in another region.
REFERENCES
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DR NIKEN TRISNOWATI, MSc, MD
Novel Combined Mutations in Keratin 5 and Keratin 14 Genes Occurring in a Mother and
Daughter with Different Severities of Epidermolysis Bullosa Simplex
N. Trisnowati1, S. Klingberg2, L. Lloyd2, L. Vonthethoff3, P. Marr3, S. Miyakis4, Y. Wang5,
G.A.C. Murrell5, D.F. Murrell1
1Dept. Dermatology, St George Hospital, University of NSW, Sydney 3Dept. Chemical
Pathology, Royal Brisbane Hospital, Brisbane Depts. 4Pathology, 5Immunology, and
6Orthopaedic Research Institute, St. George Hospital, Sydney
Introduction: Epidermolysis bullosa simplex (EBS) is caused by mutations in either the
keratin 5 or the keratin 14 gene which result in disruption of the keratin filament network. The
aim of this study is to understand the phenotypic expression of combined KRT5 and KRT14
mutations in a single kindred with EBS.
Methods: A 3 generation non-consanguinous family comprised a mother-daughter pair with
EBS. The mother had EBS Dowling-Meara phenotype, but the daughter, with less widespread
lesions, had EBS-Koebner phenotype. Mutation detection consisting of genomic DNA
extraction, PCR of KRT5 and 14, and sequencing was performed. To investigate the mutation
at the RNA level, total RNA was extracted from affected skin, followed by RT-PCR and
sequencing. Screening of 50 unrelated normal controls was performed to exclude
polymorphisms.
Results: KRT5 E168D, a novel mutation not previously described, and KRT14 A413T
mutation were identified in the mother and daughter. These mutations were confirmed in RNA
extracted from the skin lesions and not found in the normal population. KRT14 A413T, a
previously described mutation in EBS-K, was also found in the grandmother and brother, who
were clinically normal.
Conclusion: This is the first time that combined mutations in two different genes, KRT5
E168D and KRT14 A413T, have been found in any form of EB. The KRT14 A413T is
hypothesized to be incompletely penetrant in the normal family members with this mutation.
Dr Niken Trisnowati
Former MSc student, Dept of Dermatology, St George Hospital, Sydney
Currently: Dermatology Registrar, Gadjah Mada University, Yogyakarta, Indonesia
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RACHEL DE KLUYVER
INTERFERON-GAMMA, BUT NOT PERFORIN OR FAS-L, IS REQUIRED FOR KILLING
KERATINOCYTES IN VITRO AND IN VIVO
R. L. deKluyver1, L. Morritz2, I. H. Frazer1, P. F. Lambert3
1Centre for Immunology; and Cancer Research, University of Queensland, Brisbane; 2Umea
University, Umea, Sweden; and 3McArdle Laboratory for Cancer Research, University of
Wisconsin, Madison, USA
Background: We have previously demonstrated that full thickness skin grafts expressing
the human papillomavirus type16-E7 neoantigen only in keratinocytes (KCs) are not rejected
by naı¨ve recipients. Recipients immunized with E7 in adjuvant clear transplantable tumors but
fail to reject skin grafts. Rejection of skin grafts can however be achieved in some recipients
who had either received a systemic inflammatory stimulus at the time of first antigen
exposure or adoptive transfer of E7 specific, TCR alpha-chain tg spleen cells and E7
immunization. The aim of this study is to determine the minimal requirements for CD8-T cell
mediated rejection of skin grafts.
Method: To determine the effector mechanism responsible for graft rejection, antigen
specific CTL lines were established in vitro from wild type (wt) and mice rendered functionally
inactive for perforin or FasL. CTLs were co-cultured with primary keratinocytes (KCs) in vitro
or transferred into skin graft recipients.
Results: Wt, perforin(Pfp) deficient, or FasL deficient CTLs each induced rejection of skin
grafts (wt: 6/12; Pfp: 9/15; FasL: 3/13 survival). Control non-transgenic grafts are largely
ignored (wt: 12/13; Pfp:15/16; FasL:14/14 survival). Wt and Pfp CTLs prevented KC colony
formation (wt: 42%; Pfp: 80% inhibition). Neutralization of IFN-g and deletion of IFN-gR
rendered KCs resistant to colony inhibition in vitro.
Conclusion: Thus, local secretion of IFN-g is required for inhibiting KC growth in vitro and
may be required for rejection of skin grafts in vivo, while perforin and FasL are not required
absolutely. IFN-g may be acting directly to modify antigen processing and presentation or to
promote KC differentiation.
Rachel De Kluyver
University of Queensland
C.I.C.R.
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PROFESSOR LEONIE ASHMAN
A POLYMORPHISM IN THE TRANSMEMBRANE DOMAIN OF c-KIT ASSOCIATED WITH
PEDIATRIC MASTOCYTOSIS
Rowan Foster1, Ellen Byrnes1, Petranel Ferrao1, Cliff Meldrum2, Gayle Ross3, Edward
Upjohn3, Rodney Scott2, George Varigos3, Leonie Ashman1
1School of Biomedical Sciences, University of Newcastle, Callaghan NSW 2308; 2Depart-
ment of Genetics, Hunter Area Pathology Service, New Lambton, NSW 2305; 3Department
of Dermatology, Royal Children’s Hospital, Parkville VIC 3052
Background: The receptor tyrosine kinase, c-KIT, plays a key role in hemopoiesis and, in
particular, in mast cell development. Point mutations in exon 18 in the kinase domain of KIT resulting
in the substitution of Asp816 by Val cause constitutive activation of KIT in the absence of its ligand,
stem cell factor (SCF). This mutation has been found in some cases of acute myeloid leukemia,
germ cell tumors, and sinonasal lymphoma. Importantly, it has been associated with around 50% of
cases of systemic mastocytosis, in particular in those with underlying myelodysplasia. Activating
KIT mutations have not commonly been found in pediatric mastocytosis. Two sets of apparently
identical twins, in each case, both having mastocytosis, were treated at the Dermatology Clinic,
Royal Children’s Hospital, Melbourne. The occurrence of this disease in the twins suggested the
possibility of a germ-line mutation. Since KIT mutations have previously been associated with
mastocytosis, we screened all KIT exons of genomic DNA for mutations.
Methods: Genomic DNA was obtained by buccal swab from 10 pediatric mastocytosis
patients, including the two sets of twins, with approval from the Royal Children’s Hospital and
the University of Newcastle Human Ethics Committees. Similar specimens were obtained from
parents of the twins and from an unaffected sibling. PCR products corresponding to all 21 exons
were generated and examined for heterozygous substitutions by denaturing high pressure liquid
chromatography (dHPLC). Base mismatches were confirmed by direct sequencing.
Results: Both sets of twins had a heterozygous polymorphism/mutation at codon 541 in exon
10 resulting in the substitution Met541Leu in the transmembrane domain. In each case, the
substitution was present in one parent, but was not found in the one unaffected sibling who was
studied. To study the consequences of this substitution, we cloned the altered sequence into
wild-type KIT and studied its function on expression in factor-dependent murine FDC-P1 cells.
Although Met541Leu KIT did not confer factor-independence (i.e., it was not constitutively
active), the cells displayed enhanced proliferation at low levels of SCF.
Conclusion: An amino acid substitution in the transmembrane domain of c-KIT leads to an
enhanced response to low levels of SCF and appears to be associated with pediatric mastocytosis.
Leonie Ashman, PhD
School of Biomedical Sciences
University of Newcastle
Callaghan, NSW 2308
Email: leonie.ashman@newcastle.edu.au
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A/PROF DEDEE MURRELL
LATE-ONSET HERLITZ JEB MIMICKING LARYNGO-OCULO-CUTANEOUS SYNDROME
D.F. Murrell,1,2,3 K. Hamill,7 E. Pfendner,5 J. Uitto,5 E. Figuiera2,3, A. Crotty4, K. Moran,1,3 L.
Lloyd6, S. Klingberg6, I. McLean7
1Sydney Children’s Hospital, 2St George Hospital, 3University of NSW, Sydney, 4Canberra
Pathology, ACT, 5Dept Dermatology, Jefferson Univ, Philadelphia, 6Royal Brisbane Hospital
Chemical Pathology Service and 7Human Genetics Unit, University of Dundee, Scotland
Background: The patient was diagnosed with JEB at 9 months of age following
investigation of loss of fingernails, erosions with thickened tissue in the mouth, and
hoarseness off and on since birth. At 15 months of age blisters and erosions on the eyelid
margins began developing into red papules, obscuring his vision. These were excised by an
ophthalmologist and did not recur at those sites, although individual new lesions arose. The
pathology showed non-specific granulation tissue. He subsequently developed pitted teeth,
and at 3 years underwent a trachyostomy and gastrostomy at age 4 y.
Methods: IF mapping and electron microscopy of the unaffected skin was taken after
rubbing to induce a blister. Genetic screening for mutations in the LAMB3, G2 and A3 genes
was conducted.
Results: IF mapping showed a lamina lucida split with normal staining with the antibodies to
the Laminin V chains and integrins.Genetic studies identified a paternal LAMA3 R1331C at
the distal portion of the G domain. This is a splice site mutation that is predicted to cause a
premature termination codon. No maternal mutation was identified.
Conclusion: In 2003, McGrath et al described a homozygous mutation (117N) in isoform of
LAMA3 causing laryngo-oculo-cutaneous (LOC) syndrome in a Pakistani family who had no
skin lesions. DNA from our patient was tested for this mutation and LAMA3 117N was
identified as the maternal mutation. As the maternal allele makes full length laminin alpha3a
protein but with a missense mutation close to the N-terminus, it is predicted that this N
terminal region is responsible for controlling granuloma formation. About 34% of NEBR
patients with JEB have eye lesions. This is the first case of Herlitz JEB overlapping with LOC
syndrome, which could be considered as part of the EB spectrum of disorders.
DR JAMES JABBOUR
THE MANAGEMENT OF MERKEL CELL CARCINOMA: THE IMPACT OF SURGICAL
EXCISION MARGINS AND ADJUVANT RADIOTHERAPY ON SURVIVAL AND RECUR-
RENCE
J. Jabbour1,7,8, R. Scolyer3,6,8, G. Hruby5,7,8, S. Lee1,2,7,8
1Department of Dermatology, Concord Repatriation General Hospital, Sydney; 2Department
of Dermatology, 3Department of Anatomical Pathology, 4Department of 5Radiation
Oncology, 6Melanoma and Skin Cancer Research Institute (MASCRI), 7Sydney Cancer
Centre, Royal Prince Alfred Hospital, Sydney; 8University of Sydney, Sydney, Australia
Background: There is much evidence to suggest that wide surgical margins and adjuvant
radiotherapy (AR) prolong survival and time to recurrence in merkel cell carcinoma. This study
seeks to evaluate the efficacy of current treatments for merkel cell carcinoma and to describe
the merkel cell carcinoma population treated in the Central Sydney Area Health Service over
the last 12 years.
Method: Eighty-eight consecutive patients with merkel cell carcinoma managed in the
Central Sydney Area Health Service (CSAHS), with pathological diagnostic confirmation
through one of the CSAHS pathology departments between 1 January 1992 and the 31
October 2004 formed the study base. Log-rank and Cox regression analyses were performed
to determine the association of adjuvant radiotherapy (AR) and margins of excision with
survival and time to first recurrence, with adjustment for other confounders.
Results: According to a preliminary analysis, margins of excision are not significantly
associated with either survival (LR w2¼ 1.40 1df, p¼ 0.24) or recurrence (LR w2¼ 1.78 1df,
p¼ 0.18). While AR, lymph node dissection, size of the tumor, and stage are significantly
associated with both recurrence and survival using the univariate log-rank test statistic (NB:
Charlson score with survival only), only AR (HR: 2.79, 95%CI: 1.05–7.44, LR w2¼ 4.30 1df,
po0.05) and size of the tumor were shown to be independently associated with survival. AR
alone was significantly associated with recurrence by Cox multivariate regression analysis
(HR: 3.02, 95%CI: 1.34–6.88, LR w2¼ .6.75, p¼0.009).
Conclusion: This study constitutes one of the largest merkel cell carcinoma series in the
world. According to the preliminary analysis, this is the first study to demonstrate a
statistically significant relationship between AR and survival, when adjusted for other
confounders in a multivariate Cox regression. This may be related to the large sample size
and to the long follow-up period (48% of patients died before the end of the study).
Dr James Jabbour
Department of Dermatology
Concord Repatriation General Hospital
Hospital Rd, Concord NSW 2139, Australia
j.jabbour@optusnet.com.au
MISS JAMIE WE-YIN TAN
PRIMARY DEFECT IN UVB-INDUCED SYSTEMIC IMMUNOMODULATION DOES NOT
RELATE TO IMMATURE OR FUNCTIONALLY IMPARIED ANTIGEN PRESENTING CELLS
IN REGIONAL LYMPH NODES
J. W-Y. Tan, S. Gorman, P. H. Hart
Telethon Institute for Child Health Research, University of WA, Perth
Background: Ultraviolet B (UVB) radiation causes both local and systemic immunomodu-
lation. The immunological basis of systemic immunomodulation is not clear. There have been
suggestions that there is reduced expression of co-stimulatory molecules or reduced
production of IL-12 by distal antigen presenting cells.
Method: FITC or TNCB were administered to the ventral skin of BALB/c mice 4 days after
UVB irradiation (8 kJ/m2) to the shaved dorsum. After 24 h, cells isolated from the skin
draining lymph nodes were purified on density gradients and (1) stained for CD11c, MHC
class II, and the co-stimulatory molecules, CD40, CD86, (2) cultured with LPS and IFN-a for
assessment of IL-12 and PGE2 production, and (3) assessed for their ability to present
antigen (FITC) to sensitized lymphocytes. In the third experimental system, no hapten was
used. The lymph node cells isolated four days after UVB irradiation were sorted for CD11c
expression and incubated for 66 h with CD4þ cells from OVA-TCR transgenic mice in the
presence of OVA323–339. Proliferation and IFN-g and IL-10 production were measured.
Results: FITCþ /CD11cþ cells isolated from the draining lymph nodes of UVB-irradiated
mice were phenotypically mature (MHC class IIhi, CD86hi, CD40hi) and as efficient as FITCþ /
CD11cþ cells from control mice in presenting FITC to lymphocytes from FITC-sensitized
mice. CD11cþ cells in the skin-draining lymph nodes from control and irradiated mice
produced on a per cell basis similar levels of IL-12 and PGE2. FACS-sorted CD11cþ -
enriched lymph node cells were as efficient as cells from control mice at presentation of OVA
peptide to CD4þ cells from OVA-transgenic DO11.10 mice.
Conclusion: Four days after UVB irradiation, there is increased cellularity but reduced
concentration of CD11cþor FITCþ cells in the skin draining lymph nodes. This is important
when interpreting the results of other studies. As no phenotypic or functional decrease in
CD11cþ cells from UVB-irradiated mice was detected in the three experimental systems
analyzed, cells other than CD11cþ cells in the nodes of irradiated mice may be the primary
cause of systemic immunomodulation.
Miss Jamie We-Yin Tan
Telethon Institute for Child Health Research
100 Roberts Road
Subiaco WA 6008
jamiet@ichr.uwa.edu.au
DR ALLISON COWIN
EPIDERMAL WOUND HEALING IS DEFECTIVE IN MICE LACKING TETRASPANIN CD151
Allison J Cowin1, Sean M Geary2, Damian Adams1, Mark D Wright3, Leonie K Ashman2
1Child Health Research Institute and University of Adelaide, SA, 2School of Biomedical
Sciences, University of Newcastle, Callaghan NSW, 3Austin Research Institute, Kronheimer
Building, Melbourne, VIC
Background: The tetraspanin CD151 forms complexes in cell membranes with integrins,
especially alpha3 beta1, alpha6 beta 1, and alpha6 beta4 and modifies integrin-mediated cell
migration in vitro. In both simple and stratified epithelia in human tissues, CD151 is localized
mainly on the basolateral surface of cells in contact with basement membranes. We recently
generated CD151-null mice. In contrast to mice lacking alpha3, alpha6, or beta4 integrin
chains, which display skin detachment syndromes and neonatal mortality, CD151-null mice
are viable, apparently healthy, and have normal skin architecture. However, in vitro analysis
indicates that the mice have defects in platelet integrin signaling, T lymphocyte function and
greatly reduced outgrowth of keratinocytes from skin biopsies in explant cultures. The effect
of CD151 gene deletion on wound healing has been investigated in vivo.
Methods: Two full thickness 1 cm incisions were created on the backs of 24 CD151 null mice
and 24 wild type mice and the wounds analyzed. Wound gape was determined by measuring
the width of the wounds at the midway point of the 1 cm incision at all time points and
biopsies were taken at 3, 7, and 14 days post injury. Histological assessment of the wounds
was performed to identify status of wound repair. Immunhistochemical staining of wound
sections with alpha1, alpha6, beta1, beta4, and laminin antibodies was performed.
Results: Healing was significantly impaired in CD151 null mice with wounds gaping open 7
days post injury. The rate of reepithelialization of the CD151 null wounds was adversely
affected with significantly less wound area being covered by migrating epidermal cells.
Immunohistochemistry showed impaired expression of alpha6, beta4, and laminin but no
affect on beta1 and alpha1 expression.
Conclusion: Mice lacking the CD151 gene are defective in wound healing primarily due to
impairment of the reepithelialization process. This may be due to defective basement
membrane formation and epithelial cell migration.
Dr Allison Cowin
Child Health Research Institute
North Adelaide
South Australia, 5006
Australia
allison.cowin@adelaide.edu.au
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DR YEE JEN TAI
A RETROSPECTIVE ANALYSIS OF PATIENTS WITH CUTANEOUS VASCULITIS–THE ST.
VINCENT’S HOSPITAL EXPERIENCE
Y.J. Tai1, A.H. Chong1, R. Williams2, S. Cumming1, R. Kelly1
1Department of Medicine (Dermatology) and 2Department of Anatomical Pathology, St.
Vincent’s Hospital Melbourne
Background: A retrospective analysis was conducted of patients with cutaneous
leukocytoclastic vasculitis who presented to St. Vincent’s Hospital Melbourne.
Method: A list of 93 patients with histologically proven cutaneous leukocytoclastic vasculitis
was obtained from the hospital pathology database from 1997 to 2004. Each patient’s record
was reviewed in relation to age, gender, morphology, causative factors, presence of systemic
symptoms, laboratory results, treatment, and disease course. Patients were classified into
clinical syndromes using a modification of the Chapel Hill Consensus Conference definitions
of vasculitis. The clinical course was divided into acute (less than 3 months), chronic (3
months or more), and recurrent (two or more episodes less than 3 months each).
Results:
(1) Clinical classification: Patients were classified into hypersensitivity vasculitis (61.3%),
variants of cutaneous vasculitis (14.1%), Henoch-Schonlein purpura (11.8%), microscopic
polyangiitis (5.4%), polyarteritis nodosa (3.2%), Wegener’s granulomatosis (2.2%), Churg-
Strauss syndrome (1.1%), and essential cryoglobulinemic vasculitis (1.1%).
(2) Etiology: Patients were separated into primary (46.2%) and secondary vasculitis (53.8%).
The secondary causes of vasculitis were drug-related (17.2%), immune-mediated infection
(14.0%), connective tissue disease (7.5%), drug and infection (6.5%), direct bacterial
infection of vessel wall (4.3%), paraneoplastic syndrome (2.2%), and cryoglobulinemia
(1.1%).
(3) End organ involvement: Systemic involvement was found in 26.9% of patients.
(4) Clinical course: The course was acute in 59.1%, chronic in 15.1%, and recurrent in 10.8%
of patients.
Conclusion: Our analysis shows that in most patients, cutaneous vasculitis was a benign
disorder that is limited to skin. Systemic involvement was found only in 26.9% of patients.
Dr Yee Jen Tai
67/8 Wells Street,
Southbank, VIC 3006
yeejentai@yahoo.com
DR ASOKA HERAT
PRESENTATION, RESPONSE TO TREATMENT, AND OUTCOME OF ANAL CARCINOMA
AMONG HIV INFECTED INDIVIDUALS
Herat A. Hillman R.J., Whitfeld M. Meagher A., Ward R.
Background: Anal cancer, including perianal cancer, although generally a rare malignancy,
is the fourth most common malignancy among the HIV infected. There are epidemiological,
anatomical, and virological similarities with cervical cancer. Anecdotal and epidemiological
evidence suggest increasing presentations of anal cancer. Many of these cases presented to
dermatologists with in situ carcinoma or invasive perianal carcinoma, and highlight the need
for dermatologists to be aware of this condition and the way it can present. Little is known of
the impact of the HIV epidemic in the presentation, response to treatment, and outcome of
anal cancer in Australia.
Methods: A retrospective case note review was performed of the 84 patients presented
between January 1994 and September 2004 to St Vincent’s Hospital in Sydney, with a
histological diagnosis of anal squamous cell cancer. Cases were identified from the pathology
database of the hospital.
Results: The proportion of anal cancer cases known to be associated with HIV infection rose
during the study period from 16% (1 in 6) in 1994 to 68% (5 of 7) in 2003. Compared to the HIV
uninfected, people with HIV infection presented at an earlier age, more likely to be of male
gender, and more likely to have poorly differentiated histology. The HIV infected group
responded less well to treatment and had more frequent recurrences of anal cancer after
treatment. The HIV positive group, especially those with low CD4 counts, suffered a higher
rate of treatment-related complications. Early stage of presentation seems to achieve higher
treatment success, even in the presence of low CD4 counts.
Conclusion: Our data suggest that the evolving HIV epidemic may significantly change the
frequency and mode of presentation of people with anal cancer. The currently used
management strategies for anal cancer may need to be modified for HIV positive people in
order to reduce the treatment related complications and to achieve a higher rate of successful
outcome. Earlier detection of anal cancer, including perianal cancer, may result in higher
treatment success, and we need to be aware of the need for vigilant follow-up of our patients
who present to us with anal dysplasia, bowenoid papulosis, and perianal Bowen’s disease.
Further research is required to confirm these findings and to evaluate the possible role of
preventative screening programs.
DR LIANG JOO LEOW
A CASE CONTROL STUDY ON A BACTERIAL CAUSE FOR ROSACEA
L.J. Leow1,4, K. Parsi1, J. Fisher1, M. Whitfeld1,3, J. Harkness2,4, K. Shirato
1Departments of Dermatology and 2Microbiology, St Vincent’s Hospital, Sydney, 3The Skin
and Cancer Foundation of Australia and 4The University of New South Wales, Sydney.
Background: We propose that rosacea is caused by a genetic tendency to flush, which
causes transient, then persistent, vascular dilatation. This produces an increase in skin
temperature, which in turn alters the environment for normal skin flora, allowing
Propionibacterium acnes to grow. The effect of tetracycline antibiotics and erythromycin in
rosacea may be due in part to its antibiotic action against P. acnes. Further, rosacea is known
to be more severe with immunosuppression, and clinical resistance can occur.
Method: A study of patients with and without rosacea consisting of a skin biopsy and/or
swab, eyelid swab, and a questionnaire was conducted at St Vincent’s Hospital in Sydney
2005. The questionnaire measured parameters including the duration of symptoms, causes of
flushing, and previous treatment. Specimens were cultured anaerobically on BHIA and
aerobically on chocolate agar. Subcultures of P. acnes from 10 patients was also performed at
three incubation temperatures, 321C, 371C, and 421C. Patients with rosacea were
commenced on treatment with an oral tetracycline for 4 weeks and a subsequent set of
specimens was then taken.
Results: Our research indicates that symptomatology for most patients occurs begins with
flushing, usually by many years, followed by the development of telangiectasia, and later by
the development of pustules, papules, and phymatous change. The comedones which occur
with adolescent acne are no longer found, but cystic acne rosacea is more commonly found
in adults with a history of more severe acne in puberty. In vivo growth of P. acnes under
anaerobic conditions produced identifiable colonies in 4 days at 321C, 3 days at 371C, and 2
days at 421C. Final results for specimen cultures and questionnaires from both case and
control groups will be presented at the meeting.
Conclusion: The infectious etiology of rosacea has been largely discarded by the published
literature. Our research indicates that the contributory role of P. acnes in particular needs to
be further addressed. P. acnes grows more rapidly at higher temperatures, comparable to
those of patients with rosacea. This supports the argument for a bacterial cause for rosacea,
due to changes in proliferation of skin flora on a background of increased skin temperature.
Dr Liang Joo Leow
c/o Office of the Executive
St Vincent’s Private Hospital
406 Victoria Street
Darlinghurst NSW 2010
L.Leow@unsw.edu.au
MS LEILA CUTTLE
A PORCINE MODEL OF HYPERTROPHIC DEEP DERMAL PARTIAL THICKNESS BURN
FOR WOUND HEALING STUDIES
L. Cuttle, M. Kempf, M.T. Hayes, J. Mill, J.F. Fraser, R.M. Kimble
Department of Paediatrics and Child Health, University of QLD, Royal Children’s Hospital,
Brisbane, QLD
We have developed a porcine model which mimics the clinical situation of deep dermal partial
thickness burn (DDPTB) in humans. Hot water at 921 for 15 sec is used to create a contact
injury on the porcine flank under general anesthesia. The hot water is contained inside a glass
bottle of diameter 8.5 cm, with the bottom replaced with a layer of cling wrap. The wounds
take approximately 3 weeks to re-epithelialize and heal with hypertrophic scarring. Markers of
hypertrophic scar (e.g., Transforming growth factor beta, versican, decorin) were detected by
immunohistochemistry in the scar at 6 weeks and 99 days after injury. The development of
this model provides a DDPTB wound which can be used to test the efficacy of new and
existing therapies. We have developed a technique to compare the healing rates and
outcome of different wounds, utilizing clinical assessment, wound surface area (Visitrakt),
and histological analysis at post-mortem. This model is now being used to test various
products believed to be of benefit for burn injury and other wounds.
Ms Leila Cuttle
University of QLD
Department of Paediatrics and Child Health
Level 3, Foundation Building,
Royal Children’s Hospital
Herston Rd, Herston, QLD 4029
Australia
L.Cuttle@uq.edu.au
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MS ATSJE BOERSMA (MEDICAL STUDENT)
THE PREPARATION OF DERMAL AND EPIDERMAL PROTEIN EXTRACTS FOR THE
DETECTION OF AUTOIMMUNE BULLOUS DISORDERS USING AN IMMUNOBLOTTING
TECHNIQUE
A.M. BoersmaD, H. H. PasD, G. J. KloosterhuisD, M. W. Kempy, S. Kossard, L. Martiny, D.
F. Murrell, M. F. JonkmanD
Department of Dermatology, yOrthopaedic Research Institute, FThe St George Hospital
Campus, University of New South Wales, Sydney, NSW, DDepartment of Dermatology,
University Medical Centre, Groningen, Holland
Background: The immunoblotting technique is used as a diagnostic tool for detecting
antibodies in serum of patients suffering from immunobullous disorders, especially for bullous
and mucous membrane pemphigoid, epidermolysis bullosa aquisita (EBA), and the different
forms of linear IgA dermatosis. Furthermore, it is extremely useful in diagnosing
paraneoplastic pemphigus. An antigen source of human origin is preferred for optimal
detection of disease-specific antibodies. Different sources of antigens are available. Both
human skin and cultured keratinocytes can be used for preparation of antigen containing
extracts. Here we will describe the technique used to prepare epidermal and dermal extracts.
Method: Tissue samples are generally obtained from breast reduction surgery. The tissue is
washed and then frozen at 80 C in a mix of proteolytic inhibitors. Freezing is an essential
step since it simplifies the final separation along the dermal-epidermal junction. After storage,
the skin is thawed and cut in pieces. These pieces are heated so the epidermis can easily be
removed with forceps. The pieces of epidermis are immersed in extraction buffer. The
epidermal fragments are removed by centrifuging and the supernatant is stored at 80 C.
The remaining dermis can be used for preparing dermal extracts. The dermis is immersed in a
hot buffer and a mixture of protease inhibitors. After incubation, the dermis is removed and
the resulting extract is dialyzed. The extract can be stored at 80 C and treated as a normal
protein sample for SDS-PAGE.
Results: The dermal and epidermal substrates were prepared at the University Medical
Centre in Groningen, Holland. The quality of the extracts was checked with verified serum
samples. This showed the same results as the dermal and epidermal substrates used before.
The epidermal extract only reacted as expected with bullous pemphigoid sera but not with
the EBA sera. It showed 230 kDa, 180 kDa, and 120 kDa bands on the epidermal blot. The
EBA sera produced a 290 kDa band on the dermal extract only. Hence, this substrate can be
used for diagnosing the immunobullous diseases. Results will be presented of testing BP sera
from the Skin Cancer Foundation.
Immunoblotting using separated dermal and epidermal extracts is a useful tool in
diagnosing immunobullous disorders. It has been shown to be more sensitive at detecting
autoantibodies than indirect immunofluorescence. The technique is relatively simple and
easily learned. The tissue from one breast reduction or abdominopexy will provide sufficient
amounts of substrate to test approximately 325 patients when used in a micro blotting
system.
Conclusion: A vast amount of substrate can be prepared with minimal effort and expense.
As there are not many laboratories performing routine keratinocyte culture, the extraction of
epidermal and dermal extracts from tissue samples can be a useful tool for laboratories
intending to diagnose patients suffering from immunobullous disorders. It is recommended to
test the extractions after preparation, because sometimes for unknown reasons the level of
splitting is at a higher level through the basal keratinocytes, and the use of this extract will
consequently give false-positive or false-negative results.
References
Pas HH. Immunoblot assay in differential diagnosis of autoimmune blistering skin diseases.
Clin Dermatol. 19(5):622–30, 2001.
Pas HH, de Jong MJM, Jonkman MF, et al. Bullous pemphigoid: serum antibody titre and
antigen specificity. Exp Dermatol. 4:372–6, 1995
DR HEATHER BENSON
DERMAL PENETRATION ENHANCEMENT BY DERMATOPORTATION – PRELIMINARY
INVESTIGATIONS OF A NOVEL TECHNOLOGY
Heather A. E. Benson1, Namjoshi Sarika1, Jeffrey Edwards2
1Western Australian Biomedical Research Institute, School of Pharmacy, Curtin University,
Perth and 2OBJ Ltd, Perth, Western Australia
Background: Dermaportation is a novel skin penetration enhancement technology. It
involves application of an inductive energy field to the skin which we propose acts on the
ordered structure of the stratum corneum lipid bilayers to reduce the barrier effect of this
domain to the ingress of solutes. If successful, this technology may provide a means to
increase the rate and extent of skin penetration of therapeutic compounds.
Method: The use of human skin was approved by the Curtin University Medical Ethics
Committee. The influence of Dermaportation (30 min application time) on the penetration of
caffeine across excised human epidermal membranes was investigated using Franz-type
diffusion cells and standard experimental procedures. Caffeine was chosen as it is one of the
OECD recommended test solutes for in vitro skin penetration experimentation. Four different
Dermaportation energy cycles were designed and compared with passive diffusion (control).
The amount of caffeine which had penetrated the epidermis to the receptor solution
(phosphate buffered saline) was determined by HPLC with UV detection at time intervals up
to 4h post application. Caffeine flux values were determined for each of the Dermaportation
energy cycles and compared to passive diffusion.
Results: Dermaportation increased caffeine flux across human epidermis, with up to 19.24
mg.cm2.h1 compared to passive diffusion of 1.83 mg.cm2.h1.
Conclusion: This suggests that significant skin penetration enhancement can be achieved
by application of Dermaportation. Further studies to optimize this novel skin penetration
enhancement technology for application to therapeutic and cosmetic applications are being
conducted.
Dr Heather Benson
School of Pharmacy
Curtin University
GPO Box U1987
Perth WA 6845
h.benson@curtin.edu.au
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